港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

483.155

-13.603-2.74%

漲家數：7

跌家數：23

平家數：3

市盈率：- -

高：496.758

開：496.758

低：480.328

收：496.758

成交量：1.15億

成交額：26.12億

市值：3,069.30億

流通市值：2,732.98億

資料載入中...

賽諾醫療：關於參加上海證券交易所科創板2026年半年度醫療器械及醫療設備行業集體業績説明會的公告

迪哲醫藥(688192.SH)：比瑞替尼治療瀰漫性大B細胞淋巴瘤研究成果獲《血液腫瘤期刊》發表

《大行》瑞銀：中國製藥股上半年業績好壞參半首選先聲藥業(02096.HK)

阿斯达克财经

《大行》里昂：中國創新藥板塊重返Alpha主導宏觀波動或提供買入機會

阿斯达克财经

港股異動 | 維亞生物(01873)升逾5% 朗華製藥CDMO兩個新商業化項目放量為業績作出重要貢獻

中銀國際：醫藥中報業績逐步修復行業進入反轉周期

港股異動 | 和鉑醫藥-B(02142)早盤升逾4% 超長效TSLP抗體哮喘II期成功三期臨床已啓動

2026國談第五日：商保創新藥目錄價格協商開始多家藥企攜核藥、CAR-T新藥等重磅藥物進場

我武生物董事長因個人原因辭職；諾華新藥III期臨床未達主要終點 | 醫藥早參

每日经济新闻

中藥創新從「經驗方」走到「數據方」

港股震盪走弱：資源醫藥「扛大旗」，科技股「摔跟頭」

諾華製藥(NVS)股票9月8日開盤下跌12.63%：釋放什麼信號？

TradingKey中文

同源康醫藥-B(02410)董事長、執行董事兼總裁吳豫生擬增持公司股份

和鉑醫藥-B(02142)：HBM9378/WIN378治療哮喘的 II期臨床取得陽性的中期結果及III期研究啓動

超長效TSLP靶向抗體HBM9378/WIN378在哮喘2期臨床取得積極結果，並啓動3期研究

苑東生物：公司將於9月16日參加科創板2026年半年度創新藥行業集體業績説明會

勁方醫藥-B(02595)9月8日斥資154.18萬港元回購5.7萬股

智通财经网

禮邦醫藥-B(09637)：AP308治療IgA腎病的新藥臨床試驗申請獲美國食品藥品監督管理局批准

【美股盤前】中東能源風險持續升温，布油逼近100美元，油氣股集體上漲，諾華製藥重挫13%

TradingKey中文

AI 製藥迎來價值兑現期，創新藥產業打開全新增長空間

独角兽智库

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BK1574/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":483.15506,"timestamp":1789114133774,"preClose":496.75812,"halted":0,"volume":115323363,"delay":0,"changeRate":-0.027384,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-13.603058,"latestTime":"09-11 16:00:00","open":496.75812,"high":496.75812,"low":480.32812,"amount":2611810568,"amplitude":0.033074,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"pbRate":3.606253,"peRate":160.422718,"turnoverRate":0.004215,"increases":6,"decrements":25,"flats":1,"marketCap":306930068880,"floatMarketCap":273297591592},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":496.75812,"amplitude":0.033074,"preClose":496.75812,"low":480.32812,"pbRate":"3.606253","latestPrice":483.15506,"volume":115323363,"delay":0,"open":496.75812,"prevYearClose":556.26263,"prevWeekClose":532.025,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":532.025,"twentyDayClose":518.327,"sixtyDayClose":434.471,"secType":"PLATE","market":"HK","turnoverRate":0.004215,"peRate":160.422718,"marketCap":306930068880,"floatMarketCap":273297591592,"timestamp":1789114133774,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":7,"down":23,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666582190","title":"賽諾醫療：關於參加上海證券交易所科創板2026年半年度醫療器械及醫療設備行業集體業績説明會的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2666582190","media":"同花顺","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666582190?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:39","pubTimestamp":1788950340,"startTime":"0","endTime":"0","summary":"    证券日报网讯9月9日，赛诺医疗发布公告称，公司计划于2026年9月17日15：00-17：00参加上海证券交易所组织的科创板2026年半年度医疗器械及医疗设备行业集体业绩说明 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260909/c679749361.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260909/c679749361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK4585","BK1583","RSPH","HART","LGHT","GDOC","IEIH","XHE","MEDX","BK4588","09996","IHI","PTH","688108","MDEV","KSTR","LNGR","159883","BK0251","AGNG","BK1574","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666583145","title":"迪哲醫藥(688192.SH)：比瑞替尼治療瀰漫性大B細胞淋巴瘤研究成果獲《血液腫瘤期刊》發表","url":"https://stock-news.laohu8.com/highlight/detail?id=2666583145","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666583145?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 15:56","pubTimestamp":1788940569,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药 发布公告，公司自主研发的全球首创、可完全穿透血脑屏障的非共价LYN/BTK双靶点抑制剂比瑞替尼单药治疗复发/难治弥漫性大B细胞淋巴瘤II期临床研究结果正式发表于国际权威血液学期刊《血液肿瘤期刊》。TAI-SHAN9研究入组患者既往接受过1至5线系统性治疗。研究结果显示，在50mg和75mg剂量下，比瑞替尼单药治疗在不同分子亚型中均展现出广谱的抗肿瘤活性，并呈现出可管理的安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09939","BK0239","BK1574","BK1515","688192","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666983588","title":"《大行》瑞銀：中國製藥股上半年業績好壞參半  首選先聲藥業(02096.HK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666983588","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666983588?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 15:18","pubTimestamp":1788938280,"startTime":"0","endTime":"0","summary":"瑞银发表研报报告指，中国制药股上半年业绩好坏参半，在九家评级的制药公司中，有五家业绩好过市场预期，分别为翰森制药、先声药业、中生制药、石药集团及科伦药业，联邦制药表现大致符合预期，而恒瑞医药、三生制药及华东医药表现则逊预期，全数给予“买入”评级。瑞银列先声药业行业首选股，指出先声药业是唯一上调2026年指引的公司，经调整纯利增长目标由30%上调至45%，收入增长维持30%，给予目标价16.6元。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210308110543834_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210308110543834_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543624/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543624/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02096","BK1574","01477","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666304134","title":"《大行》里昂：中國創新藥板塊重返Alpha主導  宏觀波動或提供買入機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2666304134","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666304134?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 12:08","pubTimestamp":1788926880,"startTime":"0","endTime":"0","summary":"里昂发表报告指，中国创新药板块正重回以公司基本面与个股超额收益为主导的市场，公司特定基本面相对宏观因素的影响力回升。该行预期，随市场对创新药企临床及BD执行信心改善，基本面角色将愈趋重要；短期宏观波动或提供趁低买入、验证此观点的机会。该行认为，重大临床读出与BD活动加速，正面催化剂窗口正在打开。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543577/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543577/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2399975544.HKD","LU1152091168.USD","SG9999015986.USD","LU0320764599.SGD","IE00BPRC5H50.USD","LU2097828557.USD","BK1583","BK1576","01276","LU0417516902.SGD","01801","BK1515","LU1046422090.SGD","LU1820825898.SGD","BK1500","LU0348825331.USD","BK0196","BK1593","LU1813983027.USD","LU2148510915.USD","LU1188198961.HKD","09926","LU1226287792.SGD","LU2045819591.USD","LU2289578879.USD","600276","LU0348735423.USD","BK1191","KURE","LU1960683339.HKD","IE00BYV24P56.USD","LU0314109678.HKD","SG9999015978.USD","LU2580892862.HKD","01093","LU0880133367.SGD","01099","LU2039709279.SGD","LU1997244956.HKD","IE00BMCWC346.EUR","SG9999004311.SGD","BK1574","LU0463099449.HKD","BK0188","LU1794554557.SGD","IE0008369823.USD","603259","LU1255011170.USD","LU0326950275.SGD","IE00B543WZ88.USD","LU0348766576.USD","IE00BZ08YS42.EUR","LU1064130708.USD","SG9999015952.SGD","LU2476274308.USD","LU1961090484.USD","LU0348827113.USD","LU0067412154.USD","LU1226287529.USD","LU0561508036.HKD","BK1141","LU0327786744.USD","LU1152091754.HKD","LU2125910500.SGD","HK0000165453.HKD","LU0572944931.SGD","BK1197","LU1655091616.SGD","LU0072913022.USD","BK0183","LU0052750758.USD","LU0348767384.USD","LU0501845795.SGD","LU0149534421.HKD","LU0540923850.HKD","LU1831875114.USD","LU2495084118.USD","LU0405327148.USD","LU0348784397.USD","BK1161","LU0455707207.USD","LU0244354667.USD","BK1589","01177","LU1993786604.SGD","LU2476274720.SGD","LU1115378108.SGD","SHTDY","LU1328615791.USD","LU1807302812.USD","LU1064131003.USD","02595","IE00BVYPNQ40.USD","LU1969619763.USD","LU0315179316.USD","LU1720050803.USD","LU0469268626.HKD","LU1997245094.SGD","IE00BZ08YT58.USD","03692","LU2488822045.USD","IE00BVYPNP33.GBP","00867","IE00B5MMRT66.SGD","LU0607220059.USD","BK0060","LU0140636845.USD","LU2097828474.EUR","BK0114","LU0634319403.HKD","LU0708995583.HKD","LU1328277881.USD","02359","LU1997245177.USD","LU2242644610.SGD","BK0239","IE00BZ08YR35.GBP","BK1521","LU2097828631.EUR","LU2778985437.USD","LU2328871848.SGD","LU1580142542.USD","LU0417516571.SGD","LU0417516738.SGD","LU0348783233.USD","IE00BGHQDM52.EUR","LU0405327494.USD","BK0185","LU2580892789.USD","LU0640798160.USD","SG9999015945.SGD","LU1951186391.HKD","LU1226288170.HKD","LU1226288253.USD","IE0008368742.USD","SG9999004220.SGD","02162","LU0502904849.HKD","LU1781817850.SGD","BK1587","300765","SBHMY","603233","BK0226","BK0012","LU1226287875.USD","LU2097828714.EUR","BK0028","LU1146622755.USD","BK0209","IE00B031HY20.USD","LU1008478684.HKD","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666830114","title":"港股異動 | 維亞生物(01873)升逾5% 朗華製藥CDMO兩個新商業化項目放量為業績作出重要貢獻","url":"https://stock-news.laohu8.com/highlight/detail?id=2666830114","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666830114?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 11:25","pubTimestamp":1788924355,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维亚生物(01873)涨超5%，截至发稿，涨5.17%，报1.425港元，成交额754.05万港元。消息面上，维亚生物近期披露上半年业绩，招商证券指出，26H1公司收入同比+21.0%，主要得益于朗华制药CDMO两个新商业化项目放量的重要贡献。具体看，26H1朗华制药收入6.01亿元、同比+47.0%(固定汇率+52.2%)。两个重磅新商业化项目稳步推进，多肽项目已商业化上市、进入备货放量阶段；小分子项目处于PPQ生产阶段、预计2027年商业化上市，二者将成为未来几年CDMO持续增长的核心动力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","CDMO","01873","BK1574","BK1576","BK4585","VXUS","BK1141","KCAI","BK4588","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666114301","title":"中銀國際：醫藥中報業績逐步修復 行業進入反轉周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2666114301","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666114301?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 10:54","pubTimestamp":1788922458,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中银国际发布研报称，医药板块上市公司26年中报已经披露完毕，整体看，医药行业整体增长韧性十足，结构性修复持续演绎。关注底部边际修复板块，如医疗器械、原料药以及药店等医疗器械细分板块来看，医疗设备呈弱复苏态势，高值耗材增长稳健，IVD板块触底回升，低值耗材板块盈利明显修复。IVD板块，低基数效应与海外业务持续放量驱动行业盈利显著修复。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","159938","BK1515","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666097963","title":"港股異動 | 和鉑醫藥-B(02142)早盤升逾4% 超長效TSLP抗體哮喘II期成功 三期臨床已啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2666097963","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666097963?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 10:38","pubTimestamp":1788921514,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B早盘涨超4%。截至发稿，涨4.67%，报15.23港元，成交额5980.62万港元。消息面上，9月8日，和铂医药及科伦博泰宣布，其合作伙伴Windward Bio已公布POLARIS-1临床研究II期部分的阳性中期结果。该研究正在评估超长效TSLP双抗HBM9378/WIN378每年两次给药方案治疗哮喘的效果。此外，Windward Bio计划于 2027 年上半年启动第二项三期临床研究POLARIS-2。公司董事会表示，此次获纳入港股通，将为公司引入更广泛的投资者基础，进一步提升股份流动性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1574","BK1161","02142","VXUS","KCAI","BK1583","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666305240","title":"2026國談第五日：商保創新藥目錄價格協商開始 多家藥企攜核藥、CAR-T新藥等重磅藥物進場","url":"https://stock-news.laohu8.com/highlight/detail?id=2666305240","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666305240?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 09:06","pubTimestamp":1788915970,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1574","IBBQ","LNGR","MEDX","159992","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666308479","title":"我武生物董事長因個人原因辭職；諾華新藥III期臨床未達主要終點 | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2666308479","media":"每日经济新闻","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666308479?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 07:01","pubTimestamp":1788908468,"startTime":"0","endTime":"0","summary":"丨2026年9月9日星期三丨NO.1诺华制药DM1药物III期临床未达主要终点9月8日，诺华制药宣布，其评估del-desiran治疗1型强直性肌营养不良（DM1）的III期HARBOR研究未达到主要终点。公司表示，将进一步分析完整数据，并与监管机构沟通后确定后续开发路径。点评：消息放出后，诺华股价明显受挫，反映资本市场对该管线预期大幅下调。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609093868484469.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609093868484469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE0002141913.USD","09939","BK4532","BK4585","BK1574","BK4578","PPH","300357","IE0009355771.USD","LU0208291251.USD","MEDX","159938","BK0239","LU0320765489.SGD","IE00BJJMRZ35.SGD","LU0070302665.USD","IE00B2B36J28.USD","BK1515","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4007","BK0028","IE00BJT1NW94.SGD","BK4588","BK1161","LU0211331839.USD","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666654371","title":"中藥創新從「經驗方」走到「數據方」","url":"https://stock-news.laohu8.com/highlight/detail?id=2666654371","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666654371?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 23:28","pubTimestamp":1788881280,"startTime":"0","endTime":"0","summary":"传统中药源于历代医家的经验积累，但面对现代医学的检验标准，如何用可重复、可量化的数据证明其安全性和有效性，始终是中药现代化进程中绕不开的一道题。近期，《证券日报》记者在梳理相关上市公司公告时注意到，有一个词被越来越多的中药企业频繁提及——循证医学。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083868422064.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083868422064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBQ","06978","BK4159","MEDX","RCT","LNGR","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665620376","title":"港股震盪走弱：資源醫藥「扛大旗」，科技股「摔跟頭」","url":"https://stock-news.laohu8.com/highlight/detail?id=2665620376","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665620376?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 22:13","pubTimestamp":1788876780,"startTime":"0","endTime":"0","summary":"今日(9月8日)，港股市场整体震荡走弱，各大核心指数涨跌分化明显。截至收盘，恒生指数微跌0.38%，报25317.18点，单日下跌95.94点；国企指数同步小幅下行，跌幅0.38%，收报8397.32点；恒生科 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260908/c679714830.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260908/c679714830.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1161","159938","09086","07261","03034","BK1515","VGT","BK1574","09939","KCAI","03086","TTTN","07568","BK1147","BK4585","VXUS","07522","09834","BK4588","02834","XLK","07266","03455"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665376381","title":"諾華製藥(NVS)股票9月8日開盤下跌12.63%：釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2665376381","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665376381?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:48","pubTimestamp":1788875309,"startTime":"0","endTime":"0","summary":"• 在 del-desiran 的 III 期 HARBOR 临床试验宣告失败后，诺华股价下跌。\n• pelacarsen 的心血管试验同样未能达到减少心血管事件的主要终点。\n• 多项研发管线遭遇挫折，加剧了投资者的审视，并推升了结构性增长风险。","market":"fut","thumbnail":"https://resource.tradingkey.com/uploads/20251024/Novartis-369e71de347f479fa3f300f9d7904bc5.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20251024/Novartis-369e71de347f479fa3f300f9d7904bc5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156193-market-movers-nvs-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","BK1574","LU0320765489.SGD","IE0002141913.USD","LU0211331839.USD","BK4585","IE00B2B36J28.USD","01477","IE00BJJMRZ35.SGD","BK4532","NVS","LU0070302665.USD","LU0208291251.USD","MEDX","IE00B4R5TH58.HKD","BK1191","BK4007","IE00BJT1NW94.SGD","BK4588","IE0009355771.USD","BK4578","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665758793","title":"同源康醫藥-B(02410)董事長、執行董事兼總裁吳豫生擬增持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2665758793","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665758793?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:23","pubTimestamp":1788873797,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B(02410)发布公告，本公司董事长、执行董事兼总裁吴豫生博士(吴博士)已告知本公司，吴博士近日于公开市场购买本公司股份，未来可能继续根据市场情况购买本公司股份，目前预计增持总金额不超过200万港元。吴博士已向本公司承诺，他在未来一个月内通过增持获得的本公司股份将分别自购入日起自愿锁定六个月，并在锁定期内不会出售或通过其他方式转让有关股份。吴博士表示，本次股份增持的资金来自其自有资金。此次增持股份彰显其对本集团未来发展前景的坚定信念及充分信心。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1574","159938","02410","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665738153","title":"和鉑醫藥-B(02142)：HBM9378/WIN378治療哮喘的 II期臨床取得陽性的中期結果及III期研究啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2665738153","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665738153?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:54","pubTimestamp":1788872083,"startTime":"0","endTime":"0","summary":"HBM9378/WIN378是目前已知唯一一款通过双位点结合TSLP来阻断其信号通路的在研药物，能够干扰TSLP与其两个共受体在上皮细胞表面的结合。该研究亦同时评估HBM9378/WIN378对肺功能和气道炎症生物标志物的影响。其III期部分正在评估两种每年两次给药剂量的HBM9378/WIN378对比安慰剂的疗效，主要终点为重度哮喘患者的年化哮喘急性发作率。HBM9378/WIN378耐受性及安全性良好，截至数据截止日期，未观察到治疗相关严重不良事件、退出或停药。注射部位反应发生率低于1%，抗药物抗体发生率为2%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B(02142)：HBM9378/WIN378治疗哮喘的 II期临床取得阳性的中期结果及III期研究启动","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1583","02142","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111196658","title":"超長效TSLP靶向抗體HBM9378/WIN378在哮喘2期臨床取得積極結果，並啓動3期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1111196658","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111196658?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:18","pubTimestamp":1788869898,"startTime":"0","endTime":"0","summary":"聚焦呼吸系统疾病治疗领域的重大突破——和铂医药-B旗下重磅在研产品HBM9378/WIN378，一种针对胸腺基质淋巴细胞生成素的超长效抗体，近日在哮喘适应症的2期临床试验中交出亮眼答卷，数据表现令人振奋。2期临床数据显示，HBM9378/WIN378在控制哮喘症状、改善肺功能等关键指标上均展现出具有临床意义的改善，安全性与耐受性同样可圈可点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","BK1161","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378020","title":"苑東生物：公司將於9月16日參加科創板2026年半年度創新藥行業集體業績説明會","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378020","media":"证券日报 ","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378020?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:16","pubTimestamp":1788869760,"startTime":"0","endTime":"0","summary":"9月8日，苑东生物发布公告称，公司将于9月16日参加科创板2026年半年度创新药行业集体业绩说明会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-08/doc-inircrnn9176436.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-08/doc-inircrnn9176436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["KSTR","LNGR","BK1161","IBBQ","688513","MEDX","BK0239","BK1574","06978","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665135320","title":"勁方醫藥-B(02595)9月8日斥資154.18萬港元回購5.7萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665135320","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665135320?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:09","pubTimestamp":1788869377,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2026年9月8日，该公司斥资154.18万港元回购5.7万股。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493534.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK1515","09939","159938","BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320617","title":"禮邦醫藥-B(09637)：AP308治療IgA腎病的新藥臨床試驗申請獲美國食品藥品監督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320617","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320617?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:03","pubTimestamp":1788869000,"startTime":"0","endTime":"0","summary":"智通财经APP讯，礼邦医药-B 发布公告，公司近日就AP308的新药临床试验申请获美国食品药品监督管理局批准，将启动一项AP308用于治疗IgA肾病的首次人体临床试验。就公司所知，AP308为首个获准开展临床试验的IgA蛋白酶类IgAN候选药物。该平台具有优异的稳定性及成药性，并可在保留蛋白酶对IgA1高效切割活性的同时，显著延长药物体内半衰期、降低肾脏清除并减弱免疫原性，为长效、低频次给药奠定基础。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","09637","BK1161","159151","159938","MDTX","BK1515","BMED","IBBQ","BK1574","IBBJ","PSYK","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320476","title":"【美股盤前】中東能源風險持續升温，布油逼近100美元，油氣股集體上漲，諾華製藥重挫13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320476","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320476?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868800,"startTime":"0","endTime":"0","summary":"TradingKey - 美东时间周二（9月8日），美股三大股指期货盘前涨跌不一。伊朗宣布将在波斯湾和阿曼湾实施新的限制措施，也门胡塞武装则袭击沙特能源设施，推动国际油价继续走高。能源价格上涨令通胀担忧重新升温，加上日元升至2月以来最高水平，市场风险偏好受到压制。","market":"sg","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20240521/de7092af7e5b1e2c1a439a49d278289d.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20240521/de7092af7e5b1e2c1a439a49d278289d.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/analysis/stocks/us-stock/262155942-us-pre-market-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USO","BK4532","BK1574","DWT","IE00B4R5TH58.HKD","BK4007","LU0070302665.USD","UUP","LU0208291251.USD","DBO","159195","BK4588","UDN","LU0320765489.SGD","QMmain","IE00BFTCPJ56.SGD","BK4585","PPH","IE0002141913.USD","159945","IE00BJJMRZ35.SGD","BZmain","BK4570","BK4578","NVS","01477","IE00B2B36J28.USD","IE0009355771.USD","BK1191","SCO","LU0211331839.USD","DUG","IE00BJT1NW94.SGD","UCO","DDG","CLmain","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320908","title":"AI 製藥迎來價值兑現期，創新藥產業打開全新增長空間","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320908","media":"独角兽智库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320908?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 19:44","pubTimestamp":1788867840,"startTime":"0","endTime":"0","summary":"AI 制药行业已经走过早期概念炒作阶段，产业验证层级持续向上，从算法叙事正式转向管线价值兑现，行业商业化拐点正在加速到来。随着 AI 制药行业持续发展，生物测序数据需求持续扩张，设备与试剂业务打开增量空间，站在产业链上游充分受益行业整体景气上行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-08/doc-inircmes6042281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","IBBQ","MEDX","QTOC","AIPO","ARTY","VTHR","CHAT","06978","LNGR","159992","01477","BK1161","BK1191","AGIX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":5,"totalSize":344,"code":"91000000","status":"200"}]}}